Pfizer Sees Decision In Viagra Patent Case In 1-3 Months

Law360, New York (March 30, 2005, 12:00 AM EST) -- Judges in Beijing heard arguments this week in an appeal of China’s decision to withdraw Pfizer Inc.’s patent rights to the erectile-dysfunction drug Viagra.

Beijing's First Intermediate Court heard arguments from lawyers for both sides in the appeal of the State Intellectual Property Office’s decision to overturn Pfizer's patent on sildenafil citrate, the main ingredient in Viagra, Pfizer said.

Pfizer is suing China's Patent Re-examination Board (PRB) of the State Intellectual Property Office for wrongfully invalidating its patent.

Pfizer told the court the decision was based...
To view the full article, register now.

Law360 UK

UK Financial Services

Read Our Latest UK Legal News & Analysis

Financial Services Law360 UK and Insurance Law360 UK provide breaking news and in-depth analysis on U.K. and European Union regulation, enforcement, legislation, and litigation involving banks, investment firms, insurers, and more.